Is a complete IGC research report available?

No complete published report is available for IGC Pharma, Inc. (IGC) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

IGC Pharma, Inc. (IGC)

NYSEAMERICAN: IGC · USD

$0.27

-0.00 (-1.8%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-24 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first IGC analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	26.5M
Revenue (ttm)	1.1M
Net income (ttm)	-6.4M
EPS (ttm)	-$0.08
Shares out	100.1M
Volume	125,240
Beta	0.46
Price target	$4.25	+1503.8%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.1M
Net income (ttm): -6.4M
EPS (ttm): -$0.08
Market cap: 26.5M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All IGC indicators

Market & fundamental data

Available fields

212

Groups with data

Currency

USD

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001326205
Company name	IGC Pharma, Inc.
Country	United States
Country code	US
Cusip	45408X308
Employees	70
Employees Change	3%
Employees Change Percent	4.48
Enterprise value	$25.5M
Exchange	NYSEAMERICAN
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US45408X3089
Last refreshed	2026-07-24
Market cap	$26.5M
Market cap category	Nano-Cap
Price	$0.27
Price currency	USD
Rev Per Employee	15,800x
Sector	Healthcare
Sector PE	44.8
Sector PE Fwd	23.64
Sic	2834
Symbol	IGC
Website	https://igcpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-24.3%
EV Sales Forward	29.8x
EV/Sales	23.09x
FCF yield	-21.21%
P/B ratio	3.01x
P/S ratio	23.98x
PS Forward	30.95x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-731.83%
EBITDA Margin	-680.2%
Gross margin	46.2%
Gross Profit	$511,000
Gross Profit Growth	-23.16%
Gross Profit Growth Q	-47.12%
Gross Profit Growth3 Y	7.88%
Gross Profit Growth5 Y	34.06%
Net Income	$-6.4M
Net Income Growth Years	1%
Pretax Margin	-582.82%
Profit Per Employee	$-92,086
ROA	-50.31
Roa5y	-34.78
ROCE	-98.36
ROE	-83.34
Roe5y	-72.65
ROIC	-63.56

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-6.87%
Cagr15y	-15.81%
Cagr1y	-35.39%
Cagr20y	-23.33%
Cagr3y	-7.79%
Cagr5y	-37.6%
EPS Growth Years	1
Revenue Growth	-6.51x
Revenue Growth Q	23.35x
Revenue Growth Years	0x
Revenue Growth3 Y	17.72x
Revenue Growth5 Y	-3.34x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.11
Assets	$9.7M
Cash	$1.1M
Current Assets	$1.1M
Current Liabilities	$2.9M
Debt	$146,000
Debt Equity	$0.02
Equity	$8.1M
Liabilities	$1.7M
Long Term Assets	$8.6M
Long Term Liabilities	$-1.2M
Net Cash	$984,000
Net Cash By Market Cap	$3.71
Net Debt Equity	$-0.12
Tangible Book Value	$3.2M
Tangible Book Value Per Share	$0.03
WACC	6.72

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.32
Inventory Turnover	0.55
Net Working Capital	$-631,000
Quick ratio	0.79
Working Capital	$490,000
Working Capital Turnover	$-1.66

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-19.49%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-50.93%
1Y total return	-35.37%
200-day SMA	0.31
3Y total return	-21.6%
50-day SMA	0.28
50-day SMA vs 200-day SMA	50under200
5Y total return	-90.54%
All Time High	71.1
All Time High Change	-99.63%
All Time High Date	2007-12-10
All Time Low	0
All Time Low Change	264,900%
All Time Low Date	2015-01-30
ATR	0.01
Beta	0.46
Beta1y	1.35
Beta2y	0.66
Ch YTD	-5.83
High	0.27
High52	0.5
High52 Date	2025-08-27
High52ch	-46.84%
Low	0.26
Low52	0.24
Low52 Date	2026-02-09
Low52ch	9.5%
Ma50ch	-5.05%
Premarket Change Percent	-1.07
Premarket Price	$0.27
Premarket Volume	7,930
Price vs 200-day SMA	-13.37%
RSI	43.59
RSI Monthly	41.45
RSI Weekly	41.48
Sharpe ratio	-0.67x
Sortino ratio	-0.9
Total Return	-19.49%
Tr YTD	-5.83
Tr15y	-92.43%
Tr1m	-0.6%
Tr1w	3.39%
Tr3m	-24.5%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.02
Earnings Revenue Estimate	160,000x
Earnings Revenue Estimate Growth	-16.23x
Operating Income	$-8.1M
Operating margin	-731.9
Price target	$4.25
Price Target Change	$1,504

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	86,077,514%
Float Percent	86%
Net Borrowing	-3,000
Shares Insiders	14%
Shares Institutions	18.82%
Shares Out	100,091,317
Shares Qo Q	8.52%
Shares Yo Y	19.49%
Short Float	0.56%
Short Ratio	0.76
Short Shares	0.48

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-7.6M
Average Volume	389,217.75x
Bv Per Share	0.09
CAPEX	$-82,000
Ch10y	-50.93
Ch15y	-92.43
Ch1m	-0.6
Ch1w	3.39
Ch1y	-35.37
Ch20y	-99.51
Ch3m	-24.5
Ch3y	-21.6
Ch5y	-90.54
Ch6m	-11.99
Change	-1.82%
Change From Open	-1.56
Close	0.27
Days Gap	-0.26
Depreciation Amortization	571,000
Dollar Volume	33,188.6
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$-8.1M
EBITDA	$-7.5M
EPS	$-0.08
F Score	3
FCF	$-5.6M
FCF EV Yield	-22.03x
FCF Per Share	$-0.06
Financing CF	5,111,000
Fiscal Year End	March
Founded	2,005
Investing CF	-40,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-15
Last Report Date	2026-03-31
Last Split Date	2013-04-19
Last Split Type	Reverse
Last10k Filing Date	2025-06-27
Ma150	0.29
Ma150ch	-7.47%
Ma20	0.27
Ma20ch	-1.78%
Net CF	-441,000
Next Earnings Date	2026-08-06
Open	0.27
Optionable	Yes
Position In Range	37.18
Ppne	2,111,000
Pre Close	0.27
Price Date	2026-07-23
Ptbv Ratio	8.26
Relative Volume	0.32x
Revenue	1,106,000x
SBC By Revenue	182.46x
Share Based Comp	2,018,000
Tr20y	-99.51%
Tr6m	-11.99%
Us State	Maryland
Volume	125,240
Z Score	-10.12

IGC Pharma, Inc. (IGC)

Coverage state: Market snapshot only — no published research

Generate the first IGC analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · IGC

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All IGC indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on IGC

Frequently asked questions